Natural Alternatives to Pink Pills

With this long-standing tradition of framing women as less sexual and less desiring than men in mind, let’s come back to a consideration of current treatment practices. Pharmaceutical and hormonal management of female sexual dysfunction is a terrain currently being carved out further in the neoliberal marketplace. One of the most important changes recently occurred with the release of Addyi—the first FDA-approved sexual enhancement drug designed specifically for women. But Addyi is not only the first sex drug marketed to women, it is the first drug ever to target desire or libido in humans.

Sorry, this item is out of stock

Further troubling is the way medical treatments for women’s low desire have been supported by financial stakeholders who brandish their arguments under the banner of “feminism.” For instance, Sprout Pharmaceuticals-funded “patient advocacy” campaign Even the Score helped catapult the drug through the FDA evaluation process, in large part by amassing a number of groups to apply pressure to the federal advisory board based on the flawed notion that the FDA’s prior reticence to approve a sexual dysfunction drug for women constitutes blatant sexism. The campaign—which includes groups such as the National Organization for Women (NOW), Sprout Pharmaceuticals itself, and a variety of so-called “women’s health” groups who received grants and other funding incentives from Sprout—has argued that women deserve access to a drug to treat their most common sexual problem (low desire), seeing as men have had a drug to treat their most common dysfunction (erectile disorder) for over fifteen years now (hence, the argument to “even the score”). Even the Score released a short “thank you” video after the FDA approval of Addyi in August 2015 (titled “#ThankYouFDA: Our First Step Towards Sexual Health Equity” on YouTube), expressing support and gratitude to the FDA for finally moving beyond their “sexist” ways and approving a drug for women. In this short clip, the male partner in an assumedly heterosexual relationship quips that the federal approval and release of Addyi might give “new meaning to his four-hour erection.” To this, his blonde, white, female counterpart responds, “I know what to do with it!” The video ends with an image of a “Treatment Score Board,” with the text “Men = 26, Women = 1.” An image created and distributed by Even the Score, a “patient advocacy” campaign funded by Sprout Pharmaceuticals which makes Addyi and pushed for its approval by the US FDA.

Do you think a pill alone can solve low sexual desire in women?

Whereas Viagra affects (men’s) physiology only—it changes the hydraulic workings of the penis by increasing blood flow to the genital region, producing an erection in the case of so-called “impotence,” and in some cases increasing testosterone levels—Addyi affects (women’s) neurocircuitry. It goes right to the source of the so-called problem: the human—or rather the human female—brain. But what if chemical imbalances are not the real—or at least originary—reason behind any given woman’s low desire? What if desire is actually so subjective and relational that it is impossible to isolate it in the neurotransmitters of one single individual? Sociology and gender studies researchers have examined the psychosocial, cultural, and political factors that affect desire and pleasure—and which produce gender differences in these experiences—for some time.

• Pink pills are sometimes combined with other supplements, like biotin.
• They can help improve hydration and skin elasticity.
• Some formulations include synbiotics for gut health.
• They are part of natural hormone support strategies.
• Pink pills may aid in muscle recovery after workouts.
• Active ingredients vary widely between brands.
• Benefits may take weeks to become noticeable.
• Consistency and patience are key to results.
• Always check for potential interactions with medications.
• Pink pills can be a boost during stressful periods.
• Use as part of a holistic approach to health.

[4] But the quest for the inappropriately named “pink Viagra” has been one that has consumed doctors and drug-makers for the last couple of decades, after the release of sildenafil (the generic name for Viagra) and its ensuing multi-billion dollar popularity.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	2.5mg	180 + 10 Pills	154.86€ 147.49€	Buy
Viagra Generic	25mg	180 + 6 Pills	154.93€ 147.55€	Buy
Cialis Generic	20mg	10 Pills	31.49€ 29.99€	Buy
Kamagra 100 mg	100 mg	360 + 6 Pills	839.95€ 799.95€	Buy
Viagra Oral Jelly	100mg	220 + 18 Sachets	562.28€ 535.50€	Buy
Kamagra Oral Jelly	100 mg	30 + 5 Sachets	136.20€ 129.71€	Buy
Tadalista Super Active	20mg	60 + 8 Pills	230.32€ 219.35€	Buy
Viagra Generic	200mg	360 + 10 Pills	481.98€ 459.03€	Buy
Viagra Soft Tabs	100mg	90 + 6 Pills	205.31€ 195.53€	Buy
Viagra Original	100mg	8 Pills	59.84€ 56.99€	Buy
Viagra Generic	25mg	20 Pills	37.74€ 35.94€	Buy
Super Kamagra	160 mg	8 Pills	69.23€ 65.93€	Buy
Viagra Oral Jelly	100mg	30 + 5 Sachets	115.76€ 110.25€	Buy
Cialis Generic	5mg	360 + 10 Pills	268.08€ 255.31€	Buy
Viagra Super Active	100mg	360 + 30 Pills	470.93€ 448.50€	Buy
Cialis Generic	40mg	120 + 8 Pills	206.98€ 197.12€	Buy
Levitra Generic	60mg	30 + 2 Pills	109.43€ 104.22€	Buy

Finding a “feminine” equivalent to Viagra has also proved a huge failure, though, as drug after drug was tested and rejected. I wonder if this is because there is no clear corollary to an erection (specifically as an erection is understood as necessary equipment for penile-vaginal intercourse) in women, or at least nothing as visible? I wonder if it’s because whereas men are understood to be natural penetrators, sexually “healthy” women are understood first and foremost as receptors?

Real Science. Real Results.

The editor could not readily find images from this search that involved women with other women as their partners. The history of Addyi illuminates what pharmaceutical companies and the medical industry more broadly appear to think of these questions (or rather, not think), and attests to how stakeholders in these realms have continued to implement rigid ideas about sexual difference in regards to dysfunction and desire, making broad, sweeping claims about men’s and women’s sexuality in the process. In the earliest years of the twenty-first century, a German company, Boehringer Ingelheim, owned the patent to the generic version of Addyi—called flibanserin. After flibanserin was shot down for approval by the FDA in 2010 and then again in 2013 (both times because the drug’s side effects appeared to outweigh any benefits to low-desiring women in clinical trials), Boehringer Ingelheim sold the rights to the patent to a U.S.-based pharmaceutical company—Sprout Pharmaceuticals. After running new clinical trials that showed slightly lower side effects but only a marginal improvement in satisfactory sexual encounters for women with low desire, flibanserin was finally approved by the FDA in August 2015.

What should I know about Addyi before using it?

The drug was to be made officially available for public consumption in October 2015. In the interval between approval and release, before Addyi hit the shelves last fall, Valeant—a much larger, Canadian pharmaceutical company—bought Sprout Pharmaceuticals, in a $1 billion deal. Valeant is the current owner of the rights to Addyi. So, we know that Addyi has the potential to make a lot of money for big pharmaceutical companies, but what does it actually do? Addyi is considered a norepinephrine-dopamine disinhibitor, or NDDI, when compared to other antidepressants (it was initially formulated as an antidepressant before being remarketed as a sexual dysfunction drug). An erection can be easily managed with drugs, creating a situation in which a penis can best sex pills for women be used for sexual intercourse. But what if desire—for both (or all) sexes and genders—is more complicated than something as easily measurable as an erection? These questions raise other important queries about what we want from sexual medicine more broadly. How do we currently assess sexual problems?

• Pink pills frequently focus on hormonal harmony.
• They sometimes include phytoestrogens like soy isoflavones.
• Women seeking natural solutions often prefer pink pills.
• Different brands offer unique blends of ingredients.
• Some pink pills are formulated specifically for postmenopausal women.
• They may help improve skin hydration and glow.
• Pink pills are sometimes combined with herbal tea routines.
• Awareness of quality and source is crucial.
• Consumers should research product certifications before purchase.
• Pink pills are part of a broader movement toward women’s health autonomy.
• Effectiveness often depends on individual health conditions.

How do we know if a treatment is working?

Trend	Description	Expected Impact	Timeline
Personalized Pink Pills	Custom formulations based on individual DNA profiles	More effective, tailored solutions	Next 3–5 years
Natural Ingredient Focus	Increasing use of organic and natural components	Fewer side effects, greater safety	Ongoing
Tech Integration	Apps for tracking intake and effects	Enhanced user engagement	Next 2 years
Regulatory Simplification	Streamlined approval processes worldwide	Faster access to new products	Next 5–10 years

These are questions that are generally not attended to by pharmaceutical companies or even the psychologists running these companies’ drug trials, and all of their answers depend on what kind of sex we believe to be most optimal—for men, and women, to be engaging in (usually—and importantly as our sexual culture is so deeply rooted in heteronormativity—with each other). Images on a Google search for “women’s sexual dysfunction” show either sad women alone, or women with men in a situation indicating their relationship is damaged by the changes to sexual intimacy.

Brand	Market Share (%)	Origin country	Price Range	Customer Ratings
PinkBeauty	35	USA	$20-$35	4.5/5
GirlGlow	25	Canada	$15-$25	4.2/5
BellaPink	20	UK	$18-$30	4.0/5
PinkAura	10	Australia	$22-$40	4.3/5

The editor could not readily find images from this search that involved women with other women as their partners. The history of Addyi illuminates what pharmaceutical companies and the medical industry more broadly appear to think of these questions (or rather, not think), and attests to how stakeholders in these realms have continued to implement rigid ideas about sexual difference in regards to dysfunction and desire, making broad, sweeping claims about men’s and women’s sexuality in the process. In the earliest years of the twenty-first century, a German company, Boehringer Ingelheim, owned the patent to the generic version of Addyi—called flibanserin. After flibanserin was shot down for approval by the FDA in 2010 and then again in 2013 (both times because the drug’s side effects appeared to outweigh any benefits to low-desiring women in clinical trials), Boehringer Ingelheim sold the rights to the patent to a U.S.-based pharmaceutical company—Sprout Pharmaceuticals. After running new clinical trials that showed slightly lower side effects but only a marginal improvement in satisfactory sexual encounters for women with low desire, flibanserin was finally approved by the FDA in August 2015.

What is the Pink Sex Pill For Women?

I like to think cenforce tablets of it as helping you feel your sexual hunger.” It is remarkable that Dr. Marcus makes reference to women being “more receptive to sexual stimulation” in the above quote. This again raises the question of who this drug is actually for—is it for the woman who lacks desire, and suffers because of this lack? Or, is it for her purportedly more virile partner (who in many cases, is male)? In a recent article in the New York Times published immediately following the FDA approval of Addyi, Dr.

Vegetarian & Alcohol Free for Men and Women

Irwin Goldstein, a sexual specialist based in San Diego, similarly stated that women might be willing to put up with the side effects in order to garner the benefits: “Some women might find the risk of side effects acceptable if their relationships are in jeopardy because of a lack of desire.” It seems ironic that the very cost-benefit analyses or interest schemas that women are thought to “naturally” or “biologically” engage in when it comes to sex are here being prescribed to women by doctors in the sociopolitical sphere (of which conceptions of the “natural” and “biological” are arguably a part). These prescriptions also raise important questions about gender, sexuality, and health: Why should a woman put her health at risk just to please her partner? Why is her own sexual desire so sorely lacking from this representation? Why is it assumed that what she would (or should) desire most is to make her partner happy and thus to improve her “jeopardized” relationship? What type of—and whose—health are we most concerned with here? The drug was to be made officially available for public consumption in October 2015. In the interval between approval and release, before Addyi hit the shelves last fall, Valeant—a much larger, Canadian pharmaceutical company—bought Sprout Pharmaceuticals, in a $1 billion deal. Valeant is the current owner of the rights to Addyi.

The Big Pink Fight for the Little Pink Pill

This means that its mechanism of action involves allowing for more uptake of norepinephrine and dopamine, while decreasing levels of serotonin in the brain. Dopamine in particular has been found to be associated with sex drive and pleasure[5]. According to studies conducted prior to FDA approval in 2015, women who were taking Addyi reported that the average number of times they experienced “satisfying sexual events” rose from 2.8 to 4.5 times per month. It is important to note that women receiving a placebo in the same study also reported a significant increase in “satisfying sexual events,” though—an increase of 2.7 to 3.7 times per month. Side effects were also experienced by many women who took Addyi in the study, including dizziness, nausea, fatigue, sleepiness, insomnia, and dangerously low blood pressure, particularly when combined with alcohol consumption (even just two glasses of wine).

Cranberry Pills with Vitamin C

This image shows the highlighted side effects of Addyi (flibanserin). While more are listed in the full packet, this so-called “Black Box” Warning indicates that whatever benefits Addyi may have, they certainly do not come without cost. It is not to be taken lightly. Despite these very real side effects, many clinicians and practitioners have vocalized their support for the drug, stating that the potential benefits may outweigh the potential harms. Bat Sheva Marcus of the Medical Center for Female Sexuality (MCFS) in New York City, “Drug trials have shown those women who take the drug are more receptive to sexual stimulation and have more satisfying sexual activities. So, we know that Addyi has the potential to make a lot of money for big pharmaceutical companies, but what does it actually do? Addyi is considered a norepinephrine-dopamine disinhibitor, or NDDI, when compared to other antidepressants (it was initially formulated as an antidepressant before being remarketed as a sexual dysfunction drug). This means that its mechanism of action involves allowing for more uptake of norepinephrine and dopamine, while decreasing levels of serotonin in the brain.

• Pink pills are designed to be visually appealing to women.
• They sometimes include flower extracts like hibiscus.
• Pink pills can support mental focus and alertness.
• Some formulations aim to reduce menopausal hot flashes.
• They are often part of natural health approaches.
• Regular use might lead to hormone stabilization.
• Pink pills are sometimes used to enhance overall feminine vitality.
• They are typically taken with meals to improve absorption.
• Supplements should be used as directed for safety.
• The popularity of pink pills is driven by health trends.
• Scientific evidence varies for many pink pill ingredients.

Dopamine in particular has been found to be associated with sex drive and pleasure[5]. According to studies conducted prior to FDA approval in 2015, women who were taking Addyi reported that the average number of times they experienced “satisfying sexual events” rose from 2.8 to 4.5 times per month. It is important to note that women receiving a placebo in the same study also reported a significant increase in “satisfying sexual events,” though—an increase of 2.7 to 3.7 times per month. Side effects were also experienced by many women who took Addyi in the study, including dizziness, nausea, fatigue, sleepiness, insomnia, and dangerously low blood pressure, particularly when combined with alcohol consumption (even just two glasses of wine). This image shows the highlighted side effects of Addyi (flibanserin). While more are listed in the full packet, this so-called “Black Box” Warning indicates that whatever benefits Addyi may have, they certainly do not come without cost. It is not to be taken lightly. Despite these very real side effects, many clinicians and practitioners have vocalized their support for the drug, stating that the potential benefits may outweigh the potential harms. Bat Sheva Marcus of the Medical Center for Female Sexuality (MCFS) in New York City, “Drug trials have shown those women who take the drug are more receptive to sexual stimulation and have more satisfying sexual activities.

What women are saying

With this long-standing tradition of framing women as less sexual and less desiring than men in mind, let’s come back to a consideration of current treatment practices. Pharmaceutical and hormonal management of female sexual dysfunction is a terrain currently being carved out further in the neoliberal marketplace. One of the most important changes recently occurred with the release of Addyi—the first FDA-approved sexual enhancement drug designed specifically for women. But Addyi is not only the first sex drug marketed to women, it is the first drug ever to target desire or libido in humans. Whereas Viagra affects (men’s) physiology only—it changes the hydraulic workings of the penis by increasing blood flow to the genital region, producing an erection in the case of so-called “impotence,” and in some cases increasing testosterone levels—Addyi affects (women’s) neurocircuitry.

Made in USA

It goes right to the source of the so-called problem: the human—or rather the human female—brain. But what if chemical imbalances are not the real—or at least originary—reason behind any given woman’s low desire? What if desire is actually so subjective and relational that it is impossible to isolate it in the neurotransmitters of one single individual? Sociology and gender studies researchers have examined the psychosocial, cultural, and political factors that affect desire and pleasure—and which produce gender differences in these experiences—for some time. [4] But the quest for the inappropriately named “pink Viagra” has been one that has consumed doctors and drug-makers for the last couple of decades, after the release of sildenafil (the generic name for Viagra) and its ensuing multi-billion dollar popularity. I like to think cenforce tablets of it as helping you feel your sexual hunger.” It is remarkable that Dr.

Episode Transcript

Finding a “feminine” equivalent to Viagra has also proved a huge failure, though, as drug after drug was tested and rejected. I wonder if this is because there is no clear corollary to an erection (specifically as an erection is understood as necessary equipment for penile-vaginal intercourse) in women, or at least nothing as visible? I wonder if it’s because whereas men are understood to be natural penetrators, sexually “healthy” women are understood first and foremost as receptors? An erection can be easily managed with drugs, creating a situation in which a penis can best sex pills for women be used for sexual intercourse. But what if desire—for both (or all) sexes and genders—is more complicated than something as easily measurable as an erection?

by Horbaach $9.99

These questions raise other important queries about what we want from sexual medicine more broadly. How do we currently assess sexual problems? How do we know if a treatment is working? These are questions that are generally not attended to by pharmaceutical companies or even the psychologists running these companies’ drug trials, and all of their answers depend on what kind of sex we believe to be most optimal—for men, and women, to be engaging in (usually—and importantly as our sexual culture is so deeply rooted in heteronormativity—with each other). Images on a Google search for “women’s sexual dysfunction” show either sad women alone, or women with men in a situation indicating their relationship is damaged by the changes to sexual intimacy. Marcus makes reference to women being “more receptive to sexual stimulation” in the above quote. This again raises the question of who this drug is actually for—is it for the woman who lacks desire, and suffers because of this lack? Or, is it for her purportedly more virile partner (who in many cases, is male)? In a recent article in the New York Times published immediately following the FDA approval of Addyi, Dr. Irwin Goldstein, a sexual specialist based in San Diego, similarly stated that women might be willing to put up with the side effects in order to garner the benefits: “Some women might find the risk of side effects acceptable if their relationships are in jeopardy because of a lack of desire.” It seems ironic that the very cost-benefit analyses or interest schemas that women are thought to “naturally” or “biologically” engage in when it comes to sex are here being prescribed to women by doctors in the sociopolitical sphere (of which conceptions of the “natural” and “biological” are arguably a part). These prescriptions also raise important questions about gender, sexuality, and health: Why should a woman put her health at risk just to please her partner? Why is her own sexual desire so sorely lacking from this representation? Why is it assumed that what she would (or should) desire most is to make her partner happy and thus to improve her “jeopardized” relationship?

• Pink pills are sometimes formulated with herbal adaptogens.
• They aim to boost confidence and vitality.
• The combination of ingredients varies by brand.
• Some pink pills target menstrual discomfort.
• Users should start with the lowest dose to assess impact.
• Allergic reactions to certain herbs are possible.
• Pink pills are not a substitute for medical treatment.
• Combining pink pills with healthy habits yields better results.
• They are popular among women over 40 for health support.
• Pink pills may contain essential fatty acids.
• Always follow recommended guidelines for use.

What type of—and whose—health are we most concerned with here? Further troubling is the way medical treatments for women’s low desire have been supported by financial stakeholders who brandish their arguments under the banner of “feminism.” For instance, Sprout Pharmaceuticals-funded “patient advocacy” campaign Even the Score helped catapult the drug through the FDA evaluation process, in large part by amassing a number of groups to apply pressure to the federal advisory board based on the flawed notion that the FDA’s prior reticence to approve a sexual dysfunction drug for women constitutes blatant sexism. The campaign—which includes groups such as the National Organization for Women (NOW), Sprout Pharmaceuticals itself, and a variety of so-called “women’s health” groups who received grants and other funding incentives from Sprout—has argued that women deserve access to a drug to treat their most common sexual problem (low desire), seeing as men have had a drug to treat their most common dysfunction (erectile disorder) for over fifteen years now (hence, the argument to “even the score”). Even the Score released a short “thank you” video after the FDA approval of Addyi in August 2015 (titled “#ThankYouFDA: Our First Step Towards Sexual Health Equity” on YouTube), expressing support and gratitude to the FDA for finally moving beyond their “sexist” ways and approving a drug for women. In this short clip, the male partner in an assumedly heterosexual relationship quips that the federal approval and release of Addyi might give “new meaning to his four-hour erection.” To this, his blonde, white, female counterpart responds, “I know what to do with it!” The video ends with an image of a “Treatment Score Board,” with the text “Men = 26, Women = 1.” An image created and distributed by Even the Score, a “patient advocacy” campaign funded by Sprout Pharmaceuticals which makes Addyi and pushed for its approval by the US FDA.